Oesophageal cancer, oesofaguscarcinoom, esophageal cancer, active surveillance
Conditions
Interventions
Patients will undergo two clinical response evaluations (CREs) after nCRT (i.e. CRE-1 and CRE-2). During CRE-1 at 5-6 weeks after nCRT patients will undergo oesophagogastroduodenoscopy (OGD) with bite
Sponsors
Erasmus MC
Eligibility
Inclusion criteria
Inclusion criteria: - Operable patients who are planned to undergo or who recently underwent neoadjuvant chemoradiotherapy according to CROSS followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophago-gastric junction - Age =18 - Written, voluntary, informed consent.
Exclusion criteria
Exclusion criteria: - Non-FDG-avid tumour at baseline PET-CT scan - Initial treatment with endoscopic resection - Patients who underwent of who are planned to undergo definitive chemoradiotherapy - Language difficulty, dementia or altered mental status prohibiting the understanding and giving of informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint is the number of patients with adverse events registered in the SANO-2 study (safety). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the proportion of patients that adhered to the SANO active surveillance protocol (implementation) and effectiveness of active surveillance outside the SANO trial. | — |
Contacts
Public ContactCharlène van der Zijden
Erasmus MC
Outcome results
None listed